ERES

2026.01.27

Understanding Part 11 in FDA Inspections: Key Considerations for Pharmaceutical and Medical Device Companies

2026.01.27

Have Part 11 Inspections Disappeared? Understanding Current Regulatory Trends

2026.01.27

FDA Form 483 Response Requirements and Best Practices

2026.01.27

Understanding Regulatory Audits: Purpose, Misconceptions, and Modern Approaches

2026.01.27

FDA Inspection Response and the “15-Minute Rule” (Revised Edition)

2026.01.27

What Kind of Companies Provide Confidence to FDA Inspectors?

2026.01.27

Attending an FDA Inspection: Lessons from a Zero-Observation Success

2026.01.27

Keys to Successful FDA Inspection Preparedness

2026.01.27

Tips for FDA Inspection Response (Continued)

2026.01.24

Issues with Electronic Record Management Using MS-Excel